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Objectives
• Discuss the epidemiology, diagnostic criteria, and 
pathophysiology of postpartum depression (PPD)
• Review clinical evidence for the treatment options for women 
suffering with PPD
• Identify treatment regimens for women suffering with PPD
• Evaluate the implication of new drug therapies on the 
management of PPD
• Recognize side effects and monitoring parameters associated 
with drugs used in the treatment of PPD
PPD Introduction
More intense than “baby blues”
“Baby blues” symptoms: crying 
spells, mood swings, anxiety, 
difficulty sleeping 
“Baby blues” time frame: 
resolves around 2 weeks post 
deliveryCourtesy of parents.com
What is PPD?
A depressive episode that can occur during
pregnancy as well as after delivery
Courtesy of PBS
Postpartum Support International. 2013; 1-6.
Definitions
Postpartum depression differs according to 
different resources:
• DSM-V: onset within 4 weeks 
• ICD-10: onset within 6 weeks 
• Clinical research and practice: onset within 1 year  
CNS Spectr. 2015;20(1):48-59. N Engl J Med. 2016;375(22):2177-2186.  
Courtesy of Harvard Health
Diagnostic Criteria
• Diagnostic and statistical manual for mental 
disorders (DSM)
• Latest edition: DSM-5 (2013) 
Courtesy of American Psychiatric Association
American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. APA; 2013. 
Major Depressive Disorder 
(MDD) Diagnostic Criteria
One or more 
major depressive 
episodes, no 
history of mania
> 5 symptoms 
for at least 2 
weeks 
Must have 
depressed 
mood or loss 
of interest
American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. APA; 2013. 
DSM-5 Criteria
Must have at least 5 symptoms, with one being (1) or (2) 
1. Depressed mood
2. Loss of interest 
3. Weight loss or weight gain 
4. Insomnia or hypersomnia 
5. Psychomotor agitation or retardation 
6. Fatigue 
7. Feelings of worthlessness
8. Diminished ability to think or concentrate 
9. Recurrent thoughts of death, suicidal ideation, suicide attempt 
American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. APA; 2013. 
PPD Diagnostic Criteria
• Same DSM-5 criteria as MDD, but a specifier was 
created: 
• With peripartum onset 
• Onset of depressive episode during pregnancy or 
within 4 weeks postpartum 
Postpartum and antepartum depression
American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. APA; 2013. 
Prevalence
Postpartum 
depression
9%
Major depressive 
disorder in 
women
10%
J Womens Health. 2019;28(8):1068-1076.  
PPD Onset
Antepartum
38%
Postpartum
42%
J Affect Disord. 2016;203:111. 
Highest incidence of postpartum depression occurs in 
the first 6 weeks after delivery
Am J Obstet Gynecol. 2005;192(2):522-6. 
Pathophysiology
1. Increased hormone sensitivity
2. Altered levels of neuropeptides
3. Altered levels of neurotransmitters
4. Genetics 
Pathophysiology
•Decrease in estrogen, progesterone, 
and cortisol 
•Estrogen and progesterone are 
responsible for emotional processing, 
arousal, motivation, and cognition 
Increased hormone sensitivity
Front Neuroendocrinol. 2019;52:165-180.
Pathophysiology
Courtesy of Science Direct 
Pathophysiology
• Elevated monoamine oxidase-A levels 
• Metabolizes dopamine, norepinephrine, and 
serotonin 
Altered levels of neurotransmitters 
• Allopregnanolone increases during pregnancy, 
then decreases after childbirth
• Fluctuations linked to depression and anxiety
Altered levels of neuropeptides
• Family history increases risk 
Genetics 
Front Neuroendocrinol. 2019;52:165-180.
Risk Factors
• Previous history of depression
• Family history of depression, mood disorders, or anxiety 
disorders
• Sexual abuse 
• Negative attitude towards pregnancy 
• Absence of breastfeeding 
• Adolescent pregnancy 
• Lack of social support 
• Unhealthy lifestyle 
J Educ Health Promot. 2017;6:60. 
Complications of PPD
Prenatal onset associated with substance 
abuse, preeclampsia, and low birth weight
Poor infant nutrition and health 
Weakened maternal-infant bonding time
Delayed cognitive skills 
N Engl J Med. 2016;375(22):2177-2186. CNS Drugs. 2019;33(3):265-282. Neuroendocrinol. 2019;52:165-180. 
Treatment Options for PPD
Psychosocial and psychological methods: 
Mild to moderate PPD
Antidepressants: Moderate to severe 
PPD 
Hormonal therapy: Estrogen, brexanolone 
(Zulresso®) 
When to Consider 
Antidepressants
Refractory symptoms not responding 
to psychological treatment 
Severe symptoms requiring rapid 
treatment 
Patient preference 
N Engl J Med. 2016;375(22):2177-2186.  
Pharmacotherapy
May improve symptoms better than non-
pharmacological care
Continue treatment for at least 6 months after 
effective dose determined
Side effects may be increased in the postpartum 
period
Antidepressants may take up to 4-6 weeks for 
maximum effects
Pharmacotherapy
Selection based upon:
• Prior response to antidepressants
• Side effect profile
• Pregnancy category
• Infant exposure 
• Patient preference  
https://www.drugs.com/slideshow/save-money-medication-costs-1027
Antidepressant Options
Selective serotonin reuptake inhibitors 
(SSRIs)
Serotonin norepinephrine reuptake 
inhibitors (SNRIs)
Monoamine oxidase inhibitors (MAOIs)
Tricyclic antidepressants (TCAs)
Question #1
Select the antidepressant(s) that are considered 
SNRIs: 
a) Citalopram (Celexa®) 
b) Venlafaxine (Effexor®)
c) Paroxetine (Paxil®) 
d) Duloxetine (Cymbalta®) 
Quick Review
TCA
•Amitriptyline (Elavil®)
•Desipramine (Norpramin®)
•Nortriptyline (Pamelor®)
MAOI
•Phenelzine (Nardil®)
• Tranylcypromine (Parnate®)
SSRI
•Citalopram (Celexa®)
•Escitalopram (Lexapro®)
• Fluoxetine (Prozac®)
•Paroxetine (Paxil®)
•Sertraline (Zoloft®)
SNRI
•Desvenlafaxine (Pristiq®)
•Duloxetine (Cymbalta®)
• Levomilnacipran (Fetzima®)
•Venlafaxine (Effexor®)
Treatment
First line: SSRIs 
• Citalopram (Celexa®), escitalopram 
(Lexapro®), sertraline (Zoloft®)
Second line: Switch agents instead of 
augmentation
• Different SSRI, SNRI, bupropion 
(Wellbutrin®), mirtazapine (Remeron®)
Additional options:
• Trazodone (Desyrel®), Nefazodone 
(Serzone®) 
• TCAs
The Canadian Journal of Psyhiatry. 2016;61(9):502-603. 
Antidepressants to Avoid
The Canadian Journal of Psyhiatry. 2016;61(9):502-603. 
•Paroxetine (Paxil®): Risk of congenital 
cardiovascular malformations
•Clomipramine (Anafranil®): Risk of congenital 
cardiovascular malformations
•MAOIs: Interaction with medications and foods  
Pregnancy 
•Doxepin (Silenor®): High passage into breastmilk 
resulting in possible irritability, convulsions, and 
respiratory depression in the neonate
•MAOIs: Lack of breastfeeding data, interaction with 
medications and foods 
Breastfeeding
Risk Factors 
• Assess benefit of breastfeeding versus risk of 
neonatal exposure to medication
Low lactation 
risk
• Sertraline 
(Zoloft®)*
• Paroxetine 
(Paxil®)
• Nortriptyline 
(Pamelor®)
Moderately safe 
lactation risk
• Fluoxetine 
(Prozac®) 
• Citalopram 
(Celexa®)
• Venlafaxine 
(Effexor®)
• Escitalopram 
(Lexapro®)
Hazardous 
lactation risk
• Lithium 
ACOG Practice Bulletin. 2008;92:1-20. 
* Preferred 
Side Effects 
• Nausea, vomiting, diarrhea
• Headache
• Hyponatremia 
• Sexual dysfunction
• QTc prolongation (citalopram (Celexa®))
SSRIs
• Similar to SSRIs
• Seizures
• Hypertension
SNRIs
Side Effects 
• Anticholinergic side effects 
• Orthostatic hypotension
• Possible fatal overdose 
• Sedation
TCAs
• Hypertensive crisis
• Headache
• Dizziness 
• Insomnia  
MAOIs
Hormonal Therapy
Estrogen Therapy
• Limited evidence supporting use 
• Clinical review indicates reduction in symptoms 
of major depression after 12 weeks in patients 
with severe PPD
• Place in therapy: Severe PPD, not first line 
therapy
Cochrane Database Syst Rev. 2008;4:CD001690. 
Brexanolone (Zulresso®) 
Courtesy of Drug Topics 
Question #2
The mechanism of action of brexanolone 
(Zulresso®) is related to its direct, rapid 
increase of serotonin and norepinephrine in 
the brain
a) True 
b) False 
Zulresso (brexanolone) [prescribing information]. Cambridge, MA: Sage Therapeutics, Inc; June 2019. 
Question #3
Brexanolone (Zulresso®) is administered 
over 60 hours as a continuous infusion
a) True 
b) False
Zulresso (brexanolone) [prescribing information]. Cambridge, MA: Sage Therapeutics, Inc; June 2019. 
Hormonal Therapy
Brexanolone (Zulresso®)
Endogenous hormone: positive allosteric 
modulator of GABA-A receptors
Only FDA approved treatment for 
postpartum depression in adults 
Schedule IV controlled substance 
Zulresso (brexanolone) [prescribing information]. Cambridge, MA: Sage Therapeutics, Inc; June 2019. 
Administration
Single continuous IV 
infusion over 60 hours 
Approved as a risk 
evaluation and mitigation 
strategy (REMS) drug 
due to serious adverse 
reactions
Zulresso (brexanolone) [prescribing information]. Cambridge, MA: Sage Therapeutics, Inc; June 2019. 
Courtesy of Drug Topics 
Adverse Reactions
Black Box 
Warnings (BBW)
• Excessive 
sedation
• Loss of 
consciousness
Adverse Drug 
Reactions
• Suicidal thoughts 
and  behaviors
• Presyncope
• Xerostomia
Zulresso (brexanolone) [prescribing information]. Cambridge, MA: Sage Therapeutics, Inc; June 2019. 
Adverse Reactions
Terminate infusion 
if:
• Excessive 
sedation
• Loss of 
consciousness
• Hypoxic 
Resume infusion at 
the same dose or 
lower dose
Do NOT resume 
infusion
Zulresso (brexanolone) [prescribing information]. Cambridge, MA: Sage Therapeutics, Inc; June 2019. 
REMS Program  
• Healthcare settings must be 
certified in the ZULRESSO REMS to 
administer the drug
Healthcare 
settings
• Patients must be enrolled in the 
ZULRESSO REMS to be able to start 
treatment
Patients 
• Pharmacies outside the healthcare 
setting that are preparing the drug 
for administration must enroll in the 
ZULRESSO REMS
Pharmacies
Dosing
Time Dose 
0 to 4 hours 30 mcg/kg/hour
4 to 24 hours 60 mcg/kg/hour 
24 to 52 hours 90 mcg/kg/hour 
52 to 56 hours 60 mcg/kg/hour
56 to 60 hours 30 mcg/kg/hour
• No renal impairment dose adjustment 
• No hepatic impairment dose adjustment
Zulresso (brexanolone) [prescribing information]. Cambridge, MA: Sage Therapeutics, Inc; June 2019. 
Primary Literature
Brexanolone injection in postpartum 
depression: two multicenter, double-blind, 
randomized, placebo controlled, phase 3 trials 
Lancet. 2018;392(10152):1058-1070. 
Methods
Objective
• Assess the efficacy of brexanolone 
(Zulresso®) in the treatment of 
moderate to severe postpartum 
depression
Design
• Double-blind, randomized, placebo-
controlled, phase 3 clinical trials
Lancet. 2018;392(10152):1058-1070. 
Methods
Lancet. 2018;392(10152):1058-1070. 
Inclusion criteria
•18-45 YO
•< 6 mo postpartum
•Qualifying HAM-D score
•Study 1: >26
•Study 2: 20-25
•Depressive episode that 
met DSM-IV criteria
•Negative pregnancy test
Exclusion criteria
•Renal failure requiring 
dialysis
•Anemia 
•Known allergy to 
allopregnanolone or 
progesterone
•History of schizophrenia or 
bipolar disorder
Baseline Demographics
Average age: 
28 YO
62% white 
population
Average HAM-D 
score: 26 
History of 
depression: 
Study 1: 43% 
Study 2: 29%
Baseline 
antidepressant use:
Study 1: 25%
Study 2: 18%
Concomitant 
antidepressant use:
Study 1: 30%
Study 2: 25%
Lancet. 2018;392(10152):1058-1070. 
Study 1 Methods
Lancet. 2018;392(10152):1058-1070. 
138 patients with PPD 
< 6 mo post delivery
Brexanolone 90 
mcg/kg/hr titration 
(n=45) 
Brexanolone 60 
mcg/kg/hr titration 
(n=47)
Placebo (n=46) 
Study 2 Methods
Lancet. 2018;392(10152):1058-1070. 
108 patients with PPD 
< 6 mo post delivery
Brexanolone 60 
mcg/kg/hr titration 
(n=54)
Placebo (n=54) 
Primary Outcome
1° Outcome: Change from baseline in the 
Hamilton Depression Rating Scale (HAM-D) at 60 
hours  
• HAM-D determines level of depression
• 17 item scored questionnaire 
• Mild depression: 10-13 points
• Mild to moderate depression: 14-17 points
• Moderate to severe depression: >17 points
Lancet. 2018;392(10152):1058-1070. 
HAM-D Questionnaire
Depressed mood
Feelings of guilt 
Suicide
Initial insomnia 
Insomnia during the night 
Delayed insomnia 
Work and interests 
Retardation
Agitation
Psychiatric anxiety
Somatic anxiety 
Gastrointestinal somatic 
symptoms 
General somatic symptoms 
Genital symptoms 
Hypochondriasis
Weight loss 
Insight
HAM-D Items 
Points:
0- Absent 
1- Sadness 
2- Occa ional weeping 
3- Frequent weeping
4- Extreme symptoms
Secondary Outcome
HAM-D score reduction at
• 0, 2, 4, 8, 12, 24, 48, 60 and 72 hours after infusion 
• Follow-up days 7 and 30
Primary Outcome 
Results
Study 1
• Brex 60: 19.5 point 
reduction
• (95% CI -8.8 to -2.2)
• Brex 90: 17.7 point 
reduction
• (95% CI -6.9 to -0.5)
Study 2
• Brex 90: 14.6 point 
reduction
• (95% CI -4.5 to -0.5)
Lancet. 2018;392(10152):1058-1070. 
Primary Outcome 
Results 
Lancet. 2018;392(10152):1058-1070. 
Secondary Outcome 
Results
Lancet. 2018;392(10152):1058-1070. 
Secondary Outcome 
Results
• Study 1 BRX 60: -13.8 vs -19.5 (95% CI -9.5 to -1.8) 
p=0.0044
• Study 1 BRX 90: -13.8 vs -17.6 (95% CI -7.6 to 0.0) 
p=0.0481
• Study 2 BRX 90: -15.2 vs -14.7 (95% -2.0 to 3.1) 
p=0.6710
HAM-D score reduction at 30 days 
Lancet. 2018;392(10152):1058-1070. 
Adverse Drug Reactions
Lancet. 2018;392(10152):1058-1070. 
Treatment: 
41 patients
Placebo: 
22 patients 
Study 
1
Treatment: 
25 patients 
Placebo: 
24 patients
Study 
2
Adverse Drug Reactions
• Headache: 22 patients 
• Dizziness: 17 patients 
• Somnolence: 13 patients 
Most common
• Suicidal ideation: 1 patient 
• Intentional overdose attempt during follow-up: 1 
patient
• Altered state of consciousness: 1 patient 
• Syncope: 1 patient 
Serious 
Lancet. 2018;392(10152):1058-1070. 
Study Conclusions
• Brexanolone (Zulresso®) administration resulted 
in significant and clinically meaningful reductions 
in HAM-D total score at 60 hours compared to 
placebo in women suffering with moderate to 
severe PPD
• Brexanolone (Zulresso®) is associated with rapid 
onset of action and durable treatment response
• Due to minimal concomitant antidepressant use, 
brexanolone (Zulresso®) should be utilized as 
primary therapy in PPD
Lancet. 2018;392(10152):1058-1070. 
Brexanolone (Zulresso®) 
Place in Therapy
Guidelines do 
not recommend 
use
Moderate to 
severe PPD 
Adults <6 mo 
postpartum
Hospital Logistics
Sufficient budget to approve use
Medication training for physicians, nurses, and 
pharmacists 
Stored in the pharmacy’s controlled substance safe
Must be administered in a hospital through a REMS 
program 
Increased nursing staff required for drug administration 
and continuous pulse oximetry monitoring
Patient Logistics 
• REMS enrollment
• Drug education prior to administration 
• Minimum length of stay: 2.5 days 
• Must be accompanied during interaction with 
children
• Insurance coverage  
Courtesy of Women’s Mental Health
Question #4
Brexanolone (Zulresso®) has a BBW for 
suicidal thoughts and behaviors 
a) True 
b) False
Brexanolone has a warning for suicidal 
thoughts and behaviors, not a BBW.  It has a 
BBW for excessive sedation and sudden loss 
of consciousness  
Zulresso (brexanolone) [prescribing information]. Cambridge, MA: Sage Therapeutics, Inc; June 2019. 
Thank you!
Postpartum Depression! 
One IV and I am Back to 
Happy!
Gabrielle DuBruille, PharmD
PGY-1 Resident Pharmacist 
Boca Raton Regional Hospital
Baptist Health South Florida
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